Intrahepatic cholangiocarcinoma

This study aimed to see if adding focused radiation to standard chemotherapy helps people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. Only one person enrolled before the trial was stopped early, so no meaningful conclusions can…

This early-phase trial tested a two-step chemotherapy approach for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. First, patients received a standard chemo mix (mFOLFIRINOX) through the veins. Then, they got a second chemo …

This study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.

This study tested a new drug called LSTA1 added to standard treatment for people with advanced bile duct or gallbladder cancer. The goal was to see if the combination is safe and works better than standard treatment alone. The trial was stopped early, and results are not yet avai…

This study tested a combination of two drugs, donafenib and KN046, in people with advanced gastrointestinal cancers that had not responded to standard treatments. The goal was to check safety and see if the drugs could shrink tumors. The trial was stopped early, and only 15 peopl…

This early-phase trial tested a three-drug combination (ivosidenib, nivolumab, and ipilimumab) in 7 people with advanced bile duct cancer that has a specific IDH1 mutation. The goal was to check safety and find the right dose, but the study was stopped early by the sponsor before…

This phase II trial tested a combination of chemotherapy infused directly into the liver (HAIC) plus two immunotherapy drugs (atezolizumab and bevacizumab) given before and after surgery for high-risk bile duct cancer. The goal was to see if this approach could shrink tumors and …

This early-stage trial tested a new drug called NXP800 in 7 people with advanced bile duct cancer that had spread or stopped responding to treatment. The goal was to find a safe dose and see if the drug could shrink tumors by blocking a protein linked to cancer growth. However, t…

This study tested a new way to deliver an immune-boosting drug (SD-101) directly into the liver along with standard immunotherapy for people with advanced liver cancer. It included 23 adults whose cancer had not responded to prior treatment. The goal was to find a safe dose and s…

This phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so t…

This study looked at genetic mutations in tumors from 565 people with advanced gastrointestinal cancers, including liver, bile duct, gallbladder, pancreas, esophagus, and stomach cancers. The goal was to see how often these mutations could be targeted by existing drugs and to tra…

This study tested a special type of scan (SPECT/CT) to see how well it measures liver function in people with liver cancer who are getting radiation or surgery. The goal was to learn if this scan can help doctors see which parts of the liver are working well before, during, and a…